Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...